/MRTX
MRTX Stock - Mirati Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$58.70-0.17%
$0.10 (-0.17%) • Jan 22
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.83
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.89
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+67.3%upside
Target: $98.21
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MRTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$58.11 – $59.29
TARGET (TP)$98.23
STOP LOSS$54.00
RISK/REWARD1:8.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.77
52W High$64.41
52W Low$27.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $12.44M | $72.09M | $13.40M | $3.33M | $12.93M |
| Gross Profit | $11.84M | $-436,502,000 | $-285,951,000 | $-179,531,000 | $-80,946,000 |
| Gross Margin | 95.2% | -605.5% | -2134.3% | -5383.2% | -626.2% |
| Operating Income | $-759,589,000 | $-573,181,000 | $-369,363,000 | $-222,104,000 | $-102,627,000 |
| Net Income | $-740,867,000 | $-581,784,000 | $-357,937,000 | $-213,256,000 | $-98,418,000 |
| Net Margin | -5957.4% | -807.0% | -2671.6% | -6394.5% | -761.4% |
| EPS | $-13.18 | $-11.21 | $-7.96 | $-5.69 | $-3.19 |
Company Overview
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
50%
Hold / Neutral
4
40%
Sell / Underperform
1
10%
Analyst Consensus🟡 Mixed
5 Bullish5 Neutral/Bearish
Price Targets
$68
Average Target
↑ 16.5% Upside
Now
$45
Low
$68
Average
$115
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 10th 2023 | Citigroup | Upgrade | Buy | $48← $51 |
| August 9th 2023 | Piper Sandler | Resumed | Overweight | $45 |
| August 9th 2023 | B. Riley Securities | Upgrade | Buy | $45 |
| July 27th 2023 | Scotiabank | Initiation | Sector Underperform | - |
| May 25th 2023 | Oppenheimer | Upgrade | Outperform | - |
| December 14th 2022 | Needham | Initiation | Hold | - |
| December 9th 2022 | Citigroup | Downgrade | Neutral | $53← $121 |
| December 8th 2022 | JP Morgan | Downgrade | Neutral | $65← $94 |
| December 8th 2022 | BMO Capital Markets | Downgrade | Market Perform | $59← $110 |
| October 28th 2022 | B. Riley Securities | Initiation | Neutral | $72 |
| September 15th 2022 | Piper Sandler | Initiation | Overweight | $110 |
| June 7th 2022 | JMP Securities | Upgrade | Mkt Outperform | $72 |
| May 20th 2022 | Guggenheim | Upgrade | Buy | $115 |
Earnings History & Surprises
MRTXBeat Rate
50%
Last 20 quarters
Avg Surprise
-3.5%
EPS vs Estimate
Beats / Misses
10/10
Last 12 quarters
Latest EPS
$-3.51
Q1 2024
EPS Surprise History
Q2 22
-0.9%
$-3.40vs$-3.37
Q3 22
+9.9%
$-3.18vs$-3.53
Q4 22
+10.7%
$-3.09vs$-3.46
Q1 23
+6.1%
$-3.51vs$-3.74
Q2 23
+8.4%
$-3.18vs$-3.47
Q3 23
+5.9%
$-3.04vs$-3.23
Q4 23
+14.7%
$-2.49vs$-2.92
Q1 24
-32.0%
$-3.51vs$-2.66
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Feb 27, 2024 | $-2.66 | $-3.51 | -32.0% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-2.92 | $-2.49 | +14.7% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-3.23 | $-3.04 | +5.9% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-3.47 | $-3.18 | +8.4% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-3.74 | $-3.51 | +6.1% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-3.46 | $-3.09 | +10.7% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-3.53 | $-3.18 | +9.9% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-3.37 | $-3.40 | -0.9% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-3.01 | $-3.72 | -23.6% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-2.87 | $-1.55 | +46.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-2.41 | $-3.23 | -34.0% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-2.13 | $-2.67 | -25.4% | ✗ MISS |
Q1 2021 | Feb 25, 2021 | $-2.28 | $-2.08 | +8.8% | ✓ BEAT |
Q4 2020 | Nov 4, 2020 | $-2.04 | $-1.96 | +3.9% | ✓ BEAT |
Q3 2020 | Aug 6, 2020 | $-2.10 | $-1.89 | +10.0% | ✓ BEAT |
Q2 2020 | May 7, 2020 | $-1.65 | $-2.02 | -22.4% | ✗ MISS |
Q1 2020 | Feb 25, 2020 | $-1.50 | $-1.83 | -22.0% | ✗ MISS |
Q4 2019 | Nov 4, 2019 | $-1.27 | $-1.38 | -8.7% | ✗ MISS |
Q3 2019 | Aug 5, 2019 | $-1.21 | $-1.26 | -4.1% | ✗ MISS |
Q2 2019 | Apr 29, 2019 | $-0.96 | $-1.17 | -21.9% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about MRTX
What is MRTX's current stock price?
Mirati Therapeutics, Inc. (MRTX) is currently trading at $58.70 per share. The stock has moved -0.17% today.
What is the analyst price target for MRTX?
The average analyst price target for MRTX is $98.23, based on 1 analyst.
What sector is Mirati Therapeutics, Inc. in?
Mirati Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MRTX's market cap?
Mirati Therapeutics, Inc. has a market capitalization of $4.12 billion, making it a mid-cap company.
Does MRTX pay dividends?
No, Mirati Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALPN
Alpine Immune Sciences, Inc.
$64.97
Mkt Cap: $4.5B
CBAY
CymaBay Therapeutics, Inc.
$32.48
Mkt Cap: $3.7B
ISEE
IVERIC bio, Inc.
$39.95
Mkt Cap: $5.5B
KDNY
Chinook Therapeutics, Inc.
$40.39
Mkt Cap: $2.7B
MOR
MorphoSys AG
$18.96
Mkt Cap: $11.4B
MORF
Morphic Holding, Inc.
$56.99
Mkt Cap: $2.9B
MYOV
Myovant Sciences Ltd.
$26.98
Mkt Cap: $2.6B
OPT
Opthea Limited
$3.41
Mkt Cap: $0.5B
RYZB
RayzeBio, Inc. Common Stock
$62.49
Mkt Cap: $3.8B
SWTX
SpringWorks Therapeutics, Inc.
$46.99
Mkt Cap: $3.5B
Explore stocks similar to MRTX for comparison